|
Search
Collections
Benchmarks
Upload document
Organization
Takeda Pharmaceuticals America, Inc
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
2 posters
Poster
Matching-Adjusted Indirect Comparison (MAIC) of Mobocertinib vs Amivantamab in Patients with Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertions (ex20ins)
Poster
Matching-Adjusted Indirect Comparison (MAIC) of Mobocertinib vs Amivantamab in Patients with Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertions (ex20ins)